NICE to adopt orphan drugs
This article was originally published in Scrip
Executive Summary
From April 2013, NICE, the health technology appraisal institute for England and Wales, will take on the task of appraising orphan medicines. The news may worry some companies given the criticism levelled at NICE over its assessments of rare and end-of-life cancer treatments. However, it looks likely that NICE will be taking note of existing procedures for assessing such drugs and adapting its processes.
You may also be interested in...
UK Orphan Drug Access Slammed; Shire Calls For Urgent 'Access Summit'
Orphan drugs "are falling through the cracks" of the UK’s market access process, Shire's country general manager tells the Pink Sheet and calls for urgent all-party remedial talks.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.